EORTC 2029-LCG: Immunotherapy Consolidation After Radical treatment of Synchronous oligo-metastatic in Non-Small Cell Lung Cancer (NSCLC): ICARS

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508741-40-00

Acronym

EORTC 2029-LCG

Enrollment

142

Registered

2024-10-07

Start date

2025-01-14

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Brief summary

Progression Free Survival according to RECIST 1.1

Detailed description

Overall survival, Time to disease progression, Time to development of new metastatic lesions, Time to progression in oligometastatic lesions initially present at registration, AEs according to NCI-CTCAE v5.0 and SAEs, Patient-reported symptoms and treatment side-effects as measured by the EORTC QLQ-C30 and IL316 questionnaires.

Interventions

DRUGPlacebo

DRUGCEMIPLIMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression Free Survival according to RECIST 1.1	—

Secondary

Measure	Time frame
Overall survival, Time to disease progression, Time to development of new metastatic lesions, Time to progression in oligometastatic lesions initially present at registration, AEs according to NCI-CTCAE v5.0 and SAEs, Patient-reported symptoms and treatment side-effects as measured by the EORTC QLQ-C30 and IL316 questionnaires.	—

Countries

Belgium, France, Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026